- This Center has a core grant to develop a new biomarker for CFTR and is currently the central reading site for this CFTR biomarker.
- Dr. Steven Rowe is the international PI of the VX-809 study (targeting DF508 CFTR, the most common cause of CF)
- Dr. Steven Rowe is the Co-PI of the international study of PTC124 (targeting premature stop mutations in CFTR). This agent grew out of observations piloted by Dr. David Bedwell of UAB Microbiology.
- UAB was the top enrolling site in the recently completed Phase II study of VX-770 (targeting gating effects in CFTR).